A SODIUM HYALURONATE OPHTHALMIC SOLUTION FOR REDUCING DRY EYE AND ENHANCING CORNEAL WOUND HEALING AFTER PHOTOREFRACTIVE KERATECTOMY (PRK)
Objective: The objective of this work was to evaluate the efficacy and safety of 0.3% sodium hyaluronate (SH) versus hydroxypropyl-methylcellulose
(HPMC)/dextran in reducing dry eye symptoms, recovering tear film function and enhancing corneal wound healing in patients who underwent
photorefractive keratectomy (PRK) surgery.
Methods: This was a randomized, masked-assessor, controlled, parallel-group and Phase II trial. 24 patients received 1 drop of 0.3% SH or HPMC/
dextran into each eye every 2 hrs during the first month after surgery, then as needed until the day (D) 168. Efficacy and safety criteria were assessed
during six follow-up visits (D1, D3, D7, D28, D84 and D168).
Results: About 0.3% SH caused a greater improvement than control in half of the efficacy criteria, including symptoms intensity and frequency,
comfort of the eye drops, corneal haze, Schirmer I test, fluorescein and rose Bengal staining. At D28 and D84, a statistically significant difference
favoring 0.3% SH was demonstrated for fluorescein corneal staining (p=0.0114 and p=0.0308, respectively). At D3, completed re-epithelization of the
cornea was observed, 98% and 96% in 0.3% SH and control group respectively. The overall results for each of the measures used to assess the safety
indicated that 0.3% SH had an excellent safety profile over 168 days of treatment.
Conclusion: About 0.3% SH is a safe and effective treatment in reducing dry eye and enhancing corneal epithelial wound healing after PRK surgery.
Keywords: Dry eye, Artificial tears, Sodium hyaluronate, Ocular lubricants, Refractive surgery, Photorefractive keratectomy.
3. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: Determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006;47(10):4309-15.
4. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002;133(2):181-6.
5. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92.
6. Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44(11):4753-61.
7. Quinto GG, Camacho W, Behrens A. Postrefractive surgery dry eye. Curr Opin Ophthalmol 2008;19(4):335-41.
8. Krueger RR, Seiler T. The Excimer Manual: PRK Postoperative and Complications Management. New York: Little, Brown and Company; 1997. p. 121-70.
9. Mazzacane D, Braggio F. Randomized controlled trial of high-molecular-weight hyaluronic acid in dry eye syndromes. Ann Ottalmol Clin Ocul 1993;119(1):1-15.
10. Taiti L, Scrivanti M, Mencucci R, Bardi L, Salvi G. A double-masked crossover comparison of a new artificial tear preparation containing hyaluronic acid (L02A) and a reference artificial tear preparation containing hydroxypropyl-methylcellulose in dry-eye syndrome treatment. Ann Ottalmol Clin Ocul 1996;119(1):33-46.
11. Milazzo G, Papa V, Aragona P, Russo S, Russo P, Di Bella A. Efficacy of sodium hyaluronate eye drops of different osmolarities in the symptomatic treatment of dry eye patients. Adv Exp Med Biol 2002;506(Pt B):1233-5.
12. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86(2):181-4.
13. Baeyens V, Bron A, Baudouin C, Vismed/Hylovis Study Group. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Fr Ophtalmol 2012;35(6):412-9.
14. Tiffany JM. Viscoelastic properties of human tears and polymer solutions. Adv Exp Med Biol 1994;350:267-70.
15. Nakamura M, Hikida M, Nakano T, Ito S, Hamano T, Kinoshita S. Characterization of water retentive properties of hyaluronan. Cornea 1993;12(5):433-6.
16. Saettone MF, Chetoni P, Torracca MT, Burgalassi S, Giannacini B. Evaluation of mucoadhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm 1989;51:203â€‘12.
17. Gilbard JP, Carter JB, Sang DN, Refojo MF, Hanninen LA, Kenyon KR. Morphologic effect of hyperosmolarity on rabbit corneal epithelium. Ophthalmology 1984;91(10):1205-12.
18. Hamano T, Horimoto K, Lee M, Komemushi S. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol 1996;40(1):62â€‘5.
19. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol 2001;12(4):318-22.
20. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in SjÃ¶grenâ€™s syndrome patients. Br J Ophthalmol 2002;86(8):879â€‘84.
21. Pisella PJ, Godon C, Auzerie O, Baudouin C. Influence of corneal refractive surgery on the lacrymal film. J Fr Ophtalmol 2002;25(4):416â€‘22.
22. Hong JW, Kim HM. The changes of tear break up time after myopic excimer laser photorefractive keratectomy. Korean J Ophthalmol 1997;11(2):89-93.
23. Ozdamar A, Aras C, Karakas N, Sener B, Karacorlu M. Changes in tear flow and tear film stability after photorefractive keratectomy. Cornea 1999;18(4):437-9.
24. PÃ©rez-Santonja JJ, Sakla HF, Cardona C, Chipont E, AliÃ³ JL. Corneal sensitivity after photorefractive keratectomy and laser in situ keratomileusis for low myopia. Am J Ophthalmol 1999;127(5):497â€‘504.
25. Matsui H, Kumano Y, Zushi I, Yamada T, Matsui T, Nishida T. Corneal sensation after correction of myopia by photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2001;27(3):370-3.
26. Netto MV, Mohan RR, AmbrÃ³sio R Jr, Hutcheon AE, Zieske JD, Wilson SE. Wound healing in the cornea: A review of refractive surgery complications and new prospects for therapy. Cornea 2005;24(5):509â€‘22.
27. Hirabara S, Kojima T, Takahashi N, Hanabayashi M, Ishiguro N. Hyaluronan inhibits TLR-4 dependent cathepsin K and matrix metalloproteinase 1 expression in human fibroblasts. Biochem Biophys Res Commun 2013;430:519-22.
28. Saito S, Momohara S, Taniguchi A, Yamanaka H. The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis. Mod Rheumatol 2009;19(6):643-51.
29. Hiramitsu T, Yasuda T, Ito H, Shimizu M, Julovi SM, Kakinuma T, et al. Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology (Oxford) 2006;45(7):824-32.
30. Vesaluoma MH, Tervo TT. Tenascin and cytokines in tear fluid after photorefractive keratectomy. J Refract Surg 1998;14(4):447-54.
31. Tuominen I, Vesaluoma M, Teppo AM, GrÃ¶nhagen-Riska C, Tervo T. Soluble Fas and Fas ligand in human tear fluid after photorefractive keratectomy. Br J Ophthalmol 1999;83:1360-3.
32. Ramirez-Florez S, Maurice DM. Inflammatory cells, refractive regression, and haze after excimer laser PRK. J Refract Surg 1996;12(3):370-81.
33. Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocul Surf 2004;2(1):34-44.
34. Nakamura M, Hikida M, Nakano T. Concentration and molecular weight dependency of rabbit corneal epithelial wound healing on hyaluronan. Curr Eye Res 1992;11(10):981-6.
35. Gomes JA, Amankwah R, Powell-Richards A, Dua HS. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol 2004;88(6):821-5.
36. Tsiklis NS, Kymionis GD, Kounis GA, Pallikaris AI, Diakonis VF, Charisis S, et al. One-year results of photorefractive keratectomy and laser in situ keratomileusis for myopia using a 213 nm wavelength solid-state laser. J Cataract Refract Surg 2007;33(6):971-7.
37. Cherry PM, Tutton MK, Adhikary H, Banerjee D, Garston B, Hayward JM, et al. The treatment of pain following photorefractive keratectomy. J Refract Corneal Surg 1994;10 2 Suppl: S222-5.
38. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol 2005;243(6):531-8.
39. MontÃ©s-MicÃ³ R, CÃ¡liz A, AliÃ³ JL. Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. J Cataract Refract Surg 2004;30:1649-52.
40. Vogel R, Crockett RS, Oden N, Laliberte TW, Molina L, Sodium Hyaluronate Ophthalmic Solution Study Group. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol 2010;149(4):594-601.
41. Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: Randomised, double-blind, controlled, exploratory study. Br J Ophthalmol 2007;91(1):47-50.
42. McCann LC, Tomlinson A, Pearce EI, Papa V. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012;31(1):1â€‘5.
43. Kaura R, Tiffany JM. The role of mucous glycoproteins in the tear film. In: Holly FJ, editor. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, Texas: Dry Eye Institute; 1986. p. 728â€‘32.
44. Tiffany JM, Winter N, Bliss G. Tear film stability and tear surface tension. Curr Eye Res 1989;8(5):507-15.
45. Tuunanen TH, Tervo TM. Schirmer test values and the outcome of photorefractive keratectomy. J Cataract Refract Surg 1996;22(6):702-8.
46. Wilson SE. Laser in situ keratomileusis-induced (presumed) neurotrophic epitheliopathy. Ophthalmology 2001;108(6):1082-7.
47. Polunin GS, Kourenkov VV, Makarov IA, Polunina EG. The corneal barrier function in myopic eyes after laser in situ keratomileusis and after photorefractive keratectomy in eyes with haze formation. J Refract Surg 1999;15 2 Suppl: S221-4.
48. Nejima R, Miyata K, Tanabe T, Okamoto F, Hiraoka T, Kiuchi T, et al. Corneal barrier function, tear film stability, and corneal sensation after photorefractive keratectomy and laser in situ keratomileusis. Am J Ophthalmol 2005;139(1):64-71.